Amgen is batting 1.000 in its ambitious clinical program for the promising PCSK9 cholesterol drug evolocumab (AMG-145), unveiling a 5th successful Phase III study as it prepares for an FDA application that could give it first-mover status in a blockbuster field.

…read more

Source: Amgen outpaces its rivals in the race for a PCSK9 blockbuster


0 No comments